Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Abroad (travel likely)Recruiting

Conditions

Epidermolysis Bullosa Dystrophica

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Stanford University School of Medicine, Stanford, California, United States
Contact: Study coordinator (Irene Bailey-Healy) · baileyhi@stanford.edu · (650) 721-7149
Contact: Principal Investigator (Jean Tang, MD, PhD)
M. Peter Marinkovich, MD (Sub-investigator)
Anthony Oro, MD (Sub-investigator)

Study leads

Jean Tang, MD, PhD
Principal Investigator
Stanford University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa · Epidermolysis Bullosa Acquisita · Dystrophic Epidermolysis Bullosa

Abroad (travel likely)RecruitingPHASE1, PHASE2

Redwood City, United States

GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

RDEB · Recessive Dystrophic Epidermolysis Bullosa · Epidermolysis Bullosa Dystrophica, Recessive

Abroad (travel likely)RecruitingPHASE1, PHASE2

Toronto, Canada

A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

Epidermolysis Bullosa · Junctional Epidermolysis Bullosa · Epidermolysis Bullosa, Dystrophic

Abroad (travel likely)RecruitingPHASE3

Fukuoka, Japan · Fukuoka, Japan

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Epidermolysis Bullosa Dystrophica · Epidermolysis Bullosa Dystrophica, Recessive · Epidermolysis Bullosa Dystrophica Dominans

Abroad (travel likely)Recruiting

Pittsburgh, United States